Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Access to Opioid Medication in Europe (ATOME)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Germany,Switzerland,Romania,Netherlands,United Kingdom,Italy,Germany,Lithuania,Romania
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-12-01
End date: 2014-11-30
Duration (months): 60.0
Total project cost (EUR): 2812017.8
EU funding (EUR): 2449062.0
Participants: 11
Project status: CLOSED

Medicines derived from opium are very valuable in medicine practice & therefore regarded as essential medicines. However, they are generally not readily available for patients who are in need of them for medical reasons. It is estimated that over 80% of the world's population is inadequately treated, because opioid (pain relieving) medicines have been categorized as "controlled substances", due to concerns about their possible abuse. These medicines are therefore subject to strong international control, & rendered accessible. Severe under-treatment of pain is reported in more than 150 countries. In 15 countries of the EU-25, medical consumption of opioids (& other medications that are controlled under these conventions) is close to non-existent, consequently a large number of patients are not treated appropriately for moderate to severe pain. The overall goal of this project, is to undertake applied research into the reasons why opioid medicines for moderate to severe pain & for the treatment of opioid dependence are not used adequately in 12 European countries & to elaborate & disseminate tailor-made recommendations to each country for improving the accessibility, availability & affordability of controlled medicines, & disseminate these to governments, health-care professionals, other key decision-making bodies as well as to the general public. The outcome of the research will serve to underpin informed policy decisions on health systems & more effective & efficient evidence-based strategies for health therapies (pain management) in 12 European countries, thereby contributing to the realization of the activity area that frames the specific call to which this project responds, Optimizing the Delivery of Health Care to European Citizens & the overarching EU values of "universality, access to good health care, equity & solidarity, aiming to make provision that is patient-centred & responsive to individual need".

Keywords: equity and access to pain medication for patients throughout europe
GMES Space Component Data Access (GSC DA)

Framework: FP7 — Cooperation
Programme: Space
Destination: Space
Action type: Coordination and support actions
Countries involved: France
Call:  (FP7-Adhoc-2007-13, 2007)
Start date: 2007-10-01
End date: 2011-09-30
Duration (months): 48.0
Total project cost (EUR): 48000000.0
EU funding (EUR): 48000000.0
Participants: 1
Project status: CLOSED

The European Space Agency is managing the GMES Space Component Data Access (GSC-DA) project in the frame of the FP7 space programme as part of the European Space Policy focusing on coordinating the access to space-based observation data to support GMES services. For 30 years, ESA has built up experience in providing access to its own and non-ESA Missions and coordination of harmonized data access, through well established cooperation with space agencies and mission operators. The primary objective of the GSC-DA is to supply the GMES Services, and herein with priority the FP7 funded three fast track services and the two pilot service projects, with all the required space data in a seamlessly integrated, timely, secure and coordinated fashion. It aims at providing a comprehensive and coordinated access to such data allowing the capacity to link directly the different Earth Observation (EO) Data Providers and the different Service Providers using coordinating functions. The GSC-DA projects’ driver is the EO-Data Access Portfolio (EO-DAP), its maintenance and evolution. The EO-DAP is the portfolio of available EO data products from existing space based sensors that will be provided from the GMES Space Component to the operators of the GMES Services during the GMES pre-operation period 2008-2010, and beyond within an evolution cycle of both Service requirements and EO-DAP data provision. Since satellites dedicated primarily to GMES services (ESA-Sentinels) will be available only from 2011, the portfolio starts using currently available data from various EO data sources defined as Contributing Missions. The Pre-Operations Phase 2008-2010 will thus include an agreement loop with Contributing Missions and a maintenance process that will take care of the user demand and missions’ evolutions. Moreover, GSC-DA does foresee a Pre-Operations Concept for developments of GMES dedicated infrastructure adjustments, harmonization of interfaces and data products.

Keywords: data access,gmes,fp 7 projects,gmes services,gmes space component
Targeting Protein Synthesis in the Apicoplast and Cytoplasm of Plasmodium (MEPHITIS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Spain,Italy,France,Portugal,Australia,Italy,India
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2012-06-30
Duration (months): 42.0
Total project cost (EUR): 3253380.21
EU funding (EUR): 2145151.0
Participants: 8
Project status: CLOSED

The protein synthesis machinery represents one of the most useful targets for the development of new anti-infectives. Several families of broadly used antibiotics (tetracyclines, macrolides, and novel glycopeptides like vancomycin, among others) exert their function by blocking the protein synthesis machinery. Doxicycline, a tetracycline antibiotic, remains a useful tool for the prevention of paludism among travellers, despite its numerous secondary effects. And yet, very little is known about the specifics of the protein synthesis machinery in Plasmodium. A search of articles in the PubMed library with the words Plasmodium and ribosome/ribosomal in their titles will yield 6 publications since the year 2000. Only one article contains the words tRNA (or transfer RNA) and Plasmodium in its title, in the same period. And only one article in PubMed (Snewin et al., 1996) contains the words Plasmodium and ‘tRNA synthetase’ (or ligase) in its title. This lack of information about this central metabolic pathway in Plasmodium clearly blocks the possibility of transferring the knowledge in protein synthesis to the development of new anti-malarial drugs directed against the translational machinery of the parasite. Thus, the study of components of the genetic code in Plasmodium has the potential for providing new and important information on the biology of the parasite and, more importantly, open new leads for the development of novel anti-malarials. This proposal coordinates an effort to study tRNA biology in Plasmodium falciparum. It contains specific schemes for the development of new pharmacological screens, several initiatives for the selection of new potential anti-malarial drugs, and projects designed to answer fundamental questions regarding protein synthesis in Plasmodium. The laboratories in MEPHITIS accumulate a large body of experience in the biology of this parasite, and in different aspects of tRNA biology in model species.

Keywords: malaria,plasmodium falciparum,drug development,protein synthesis,drug screening,apicoplast,trna,aminoacyl-trna synthetases,elongation factors
Development of targeted DNA-Chips for High Throughput Diagnosis of NeuroMuscular Disorders (NMD-CHIP)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: France,France,Sweden,Belgium,United Kingdom,Hungary,Italy,Netherlands,Germany,Germany,United Kingdom,Switzerland
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-10-01
End date: 2011-09-30
Duration (months): 36.0
Total project cost (EUR): 3773723.4
EU funding (EUR): 2907735.0
Participants: 14
Project status: CLOSED

Inherited Neuromuscular Diseases (NMD) form a large group of diseases including Limb-Girdle Muscular Dystrophies (LGMD), Congenital Muscular Dystrophies (CMD), Duchenne and Becker Muscular Dystrophies (DMD/BMD), or Charcot-Marie-Tooth disease (CMT). Within a given disease group genetic and clinical heterogeneity is the hallmark. The precise diagnostic of neuromuscular diseases thus requires extensive clinical examination and targeted complementary tests. Additionally, since many of the disease causing mutations are known, molecular and genetic tests are performed to confirm and precise the diagnostic. According to presently available technologies, this is highly complex and time consuming. Thus, many patients remain devoid of genetic confirmation of their disease. More importantly, new cutting edge therapies cannot and will not be possibly envisaged in absence of a precise genetic diagnosis. New molecular diagnosis tools, enabling quick, reliable and cost-effective sequencing of numerous NMD genes are thus required. The development of such tools would allow performing the genetic diagnostic of NMDs patients. DNA chips have the potential to address this issue, in a time and cost effective way. The goal of this project is to i) design and validate a DNA Chip for sequencing genes responsible for LGMDs, CMDs, DMD/BMD, and CMTs, and ii) use the DNA Chip technology to identify new genes/mutations involved in these inherited NMD and increase the molecular diagnosis/patients ratio. This approach will be based on a gene candidate approach. NMD-Chip will thus lead to the development of a novel sensitive and reliable (98%) diagnostic tool, with time and cost effectiveness dedicated to neuromuscular disorders. In total, NMD-Chip, based on human genome knowledge and an advanced read out technology, will give patients an easy access to molecular diagnosis and will thus allow them to benefit from cutting edge therapies which are currently developed.

Keywords: inherited neuromuscular disorders,diagnostics,molecular genotyping,dna chip,high-throughput
Translational Research on Combating Antimicrobial Resistance (TROCAR)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Spain,Portugal,France,Finland,Italy,Netherlands,France,United Kingdom,Germany,Spain,Spain,Greece,Germany,United Kingdom
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2012-06-30
Duration (months): 42.0
Total project cost (EUR): 3948928.8
EU funding (EUR): 2999444.0
Participants: 14
Project status: CLOSED

The health care systems of most European countries are based on a continuum from acute care hospitals, though other health care facilities to the community. Such a framework provides the perfect opportunity for the wide-spread dissemination of high-risk resistant clones or genetic resistant elements. The driving concept of TROCAR is to investigate the fundamentals of the epidemiology of new highly virulent multiresistant strains of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus spp., Extended-spectrum, metallo- and acquired AmpC beta-lactamase producing Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii will focus on three major strategic aims: 1. The definition of the major high-risk resistant clones based on an appropriate representative collection and new clinical strains obtained during molecular epidemiological studies, in hospitals and laboratories collaborating with their respective National Excellence Laboratories in European countries using a standardised protocol. 2. The promotion of collaborative European research to investigate, by genomic and proteomic approaches, specific traits associated with virulence, transmission, persistence and resistance of epidemic clones in comparison with non-epidemic clones as well as resistance determinants and their genetic location in horizontal gene transfer units and their genetic environment. 3. The development of bioinformatics tools to fully exploit the genomics data and allow the rapid identification of resistant strains with heightened epidemic potential. By combining the outputs of the project it will be possible to provide tools for monitoring the spread of key community and nosocomial pathogens, to provide the scientific basis for an early warning system when isolates of a particular epidemicity appear in the community and nosocomial settings, to characterise specific genetic elements carrying resistance genes encoding, and to establish t

Keywords: methicillin resistant staphylococcus aureus,vancomycin-resistant enterococcus spp.,esbl,metallo-beta-lactamases,ampc,viruenterobacteriaceae,multidrug,resistance,p. aeruginosa,a. baumannii.
Unlocking a feather bioeconomy for keratin-based agricultural products (UNLOCK)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Theme: Public-private partnerships
Destination: Bio-based Industries
Action type: Innovation actions
Partnership: BBI (Art-187)
Countries involved: Spain,Spain,Spain,Ireland,Spain,Spain,Cyprus,Belgium,Poland,Poland,Poland,Belgium,Croatia,Sweden,Sweden,France
Call: Resolve supply-chain hurdles for turning residual waste streams into functional molecules for food and/or non-food market applications (H2020-BBI-JTI-2020, 2020)
Start date: 2021-05-01
End date: 2025-04-30
Duration (months): 48.0
Total project cost (EUR): 7444822.47
EU funding (EUR): 5108554.0
Participants: 18
Project status: SIGNED

Only in Europe 3,6 million tonnes of feathers are generated per year as waste of the poultry sector. Around 25% is used for animal feed or fertilisers while the rest is disposed in landfills or incinerated. Feathers contain nearly 90% of keratin, a valuable protein which can source for biodegradable materials, such as bioplastics for agriculture. However, to unlock the full potential of feathers as raw material for functional molecules, there are many technical, logistic and market hurdles to solve in the supply chain for the takeoff of profitable value chains and for the easy market uptake of keratin-based products. UNLOCK will design and demonstrate economically & environmentally sustainable value chains led by the primary sector, which will generate innovative bio-based functional products for agricultural applications: forest/seed trays, nonwoven geotextiles, mulch films and hydroponic foams. Keratin-based materials will outperform their fossil-based counter parts by providing additional functionalities during the product life span and environmental benefits at the end-of-life (controlled biodegradability, enrichment of organic nitrogen to soil and zero waste generation). UNLOCK will create 4 new bio-based value chains, 4 new agricultural consumer goods and at least 3 cross sector interconnections among the primary sector (poultry sector), the bioplastics industry and the agricultural sector, opening up new innovation-led market and job opportunities in the EU bioeconomy. UNLOCK conversion technologies will evolve from TRL5 to 7, demonstrating the full potential of keratin for circular bio-based plastics, through a multidisciplinary consortium of 15 partners (8 SMEs), supported by a strong stakeholder board. UNLOCK will enable the setup of 2 first-of-its-kind commercial biorefineries after the end of the project. The co-creation and replication will be reinforced through a specific regional cluster approach to multiply the impacts during and after the project.

Keywords: feathers,keratin,functional proteins,bioeconomy,poultry,primary sector,biodegradable plastics
Tackling Antimicrobial Resistance through improved livestock Health and Welfare (HealthyLivestock)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Theme: Sustainable agriculture and forestry
Action type: Research and Innovation actions
Countries involved: Germany,Germany,Germany,Italy,Cyprus,Belgium,China,Belgium,Poland,France,France,France,Netherlands,United Kingdom,United Kingdom
Call: Alternative production system to address anti-microbial drug usage, animal welfare and the impact on health (H2020-SFS-2017-2, 2017)
Start date: 2018-09-01
End date: 2023-02-28
Duration (months): 54.0
Total project cost (EUR): 6982237.75
EU funding (EUR): 4993710.0
Participants: 26
Project status: SIGNED

HealthyLivestock aims to reduce antimicrobial (AM) use by the pig and broiler industries in China and Europe, and consequent residues in meat and the environment, by improving animal health & welfare without compromising productivity. Phase 1, combining efforts from 5 Chinese and 8 EU academic partners, will include novel scientific approaches in 4 interlinked strategies to reduce AM need. 1) Biosecurity: reducing risk of pathogen presence within a farm through zoning-based Health & Welfare plans, including animal based indicators of success. 2) Resilience: increasing ability of animals to cope with endemic diseases, through novel stress-reducing housing systems and probiotic improvement of gut health. 3) Rapid detection: applying precision farming techniques to facilitate early detection, diagnosis and intervention of health & welfare problems. 4) Precision medication: using pharmacokinetics to target AM to only individuals or groups in need. Phase 2 will validate the technical innovations by establishing their societal acceptability and economic viability. It will also assess the relationships between the Health & Welfare plans, the level of pathogens on the farm and AM residues in product and manure. In phase 3 the project’s industrial partners dedicate their network and expertise to knowledge exchange. The Federation of Veterinarians of Europe will lead dissemination of the scientific findings through Technical Notes. China’s only animal welfare standard setting organisation ICCAW, and Europe’s leading organisation GLOBALG.A.P., will strengthen their Quality Assurance schemes. Zoetis, the world’s largest veterinary pharmaceutical company, will develop and disseminate their pig and poultry advisory apps for global use. Finally, HealthyLivestock will support Chinese and EU policy making through CAAS and its links with International Veterinary Collaboration for China, and through the forthcoming EU Animal Welfare Platform and Network of Welfare Reference Centres.

Keywords: biosecurity,resilience,animal welfare,animal health
LIGHTHOUSE: concentrated thermal solar power directly connected to the heating and cooling systems of buildings at the local level. (LIGHTHOUSE)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure, clean and efficient energy
Action type: SME instrument
Countries involved: Greece
Call: Stimulating the innovation potential of SMEs for a low carbon and efficient energy system (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-08-01
End date: 2017-01-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The idea of LIGHTHOUSE (patented) is pretty simple, we concentrate the solar power, as we used to do when we were playing as children, in order to transform the power of the sun into pure heat in high temperature and connect it, to our building heating and/or cooling systems, and this way reduce the costs up to 60% and protect the environment at the same time. LIGHTHOUSE brings the power of the big solar power plants at every building at the local level, in a financially feasible way, allowing collection of solar energy at high temperatures, with excellent and reliable performance all year round, all day long, with maximum efficiency. Solar heating and cooling is a key player in the EU energy policy framework, especially towards achieving the 2020 targets, and European Energy Council describes the heating and cooling need in buildings at the local level, as a “Sleeping Giant”. LIGHTHOUSE primary target is to reduce the fossil fuels that are burned inside the cities, and the electricity consumed from the city’s grid, for heating and cooling our buildings (49% of the global energy consumption), much more efficient than any other solutions like photovoltaic or CPV which produces only electricity and not high quality thermal energy (heat that is needed for heating and cooling) . The aim of the feasibility study is to identify and select the best materials and components in terms of cost-effectiveness and availability, by means of a market research; then, the performance of the key parts will be evaluated by testing several Fresnel lens (key component); in parallel, a study on the LIGHTHOUSE design will be carried out, taking into account issues like safety, durability, efficiency and aesthetics, together with cost-effectiveness. The systematic collection of results will enable the participating SME to approach Phase2 with a completed prototype design and a first market research done, in order to proceed with pilot implementations in Mediterranean countries .

Keywords: solar power,energy,environment,heating,cooling,district heating,concentrated solar thermal energy
Innovative sustainable ENCAPsulation systems for improving human HEALTH and well-being (ENCAP4HEALTH)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Research and innovation staff exchange
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Ireland,Germany,Ireland,Argentina,Germany,France,Netherlands,United Kingdom,Chile,Denmark,United Kingdom
Call: Research and Innovation Staff Exchange (H2020-MSCA-RISE-2019, 2019)
Start date: 2020-01-01
End date: 2024-06-30
Duration (months): 54.0
Total project cost (EUR): 607200.0
EU funding (EUR): 607200.0
Participants: 12
Project status: SIGNED

Improvement and maintenance of health, particularly in ageing societies, is a major challenge defined in H2020. In this context, the objective of ENCAP4HEALTH is to develop innovative concepts for biopolymer-based microcapsules resulting in a new generation of highly functional delivery systems for functional food ingredients. Experts have emphasized for a long time that new methods and materials are required to improve functionality, digestibility and absorption of these so-called bioactives. With an increasing awareness for zero-waste production and reduction of the environmental impact of food processing, opportunities to create a new generation of encapsulation systems open up. ENCAP4HEALTH will bring together more than 50 international experts with ample expertise from 12 different institutions (technical, medical and traditional universities, SMEs and multinational companies). The network aims to identify new biopolymers and to develop more efficient and sustainable processing technologies for encapsulation. The action is divided into six work packages, three of them devoted to scientific research and three to training, career development, dissemination and exploitation as well as management. Multiple training activities related to these work packages have been specifically designed to improve the skills of the consortium members and to promote their career development. Gender aspects will adequately be addressed in training and research. Exploitation of results will boost innovation and present societal and economic benefits by producing more effective functional food applying new and optimized encapsulation techniques. ENCAP4HEALTH will lead to a greater affordability of multiple health and food applications opening market opportunities in the food sector, that will spread out to agriculture, feed, pharma and even the biomedical sector.

Keywords: encapsulation,delivery systems,biopolymers,plant protein,bioactives,smart processing,digestion